Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer.

Literature DB >> 29268467

KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer.

Hidehito Horinouchi¹.

Abstract

Entities: Disease

Year: 2017 PMID： 29268467 PMCID： PMC5720970 DOI： 10.21037/jtd.2017.10.135

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

7 in total

1. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors: Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal: Lancet Date: 2016-12-13 Impact factor: 79.321

2. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors: Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal: Lancet Oncol Date: 2016-10-10 Impact factor: 41.316

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors: Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245

5. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors: Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal: Lancet Date: 2014-06-02 Impact factor: 79.321

6. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

7. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.

Authors: A Lindauer; C R Valiathan; K Mehta; V Sriram; R de Greef; J Elassaiss-Schaap; D P de Alwis
Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-11-08

7 in total

2 in total

Review 1. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors: Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal: Zhongguo Fei Ai Za Zhi Date: 2019-06-20

2. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer.

Authors: Matthew P Humphries; Sean Hynes; Victoria Bingham; Delphine Cougot; Jacqueline James; Farah Patel-Socha; Eileen E Parkes; Jaine K Blayney; Michael A O'Rorke; Gareth W Irwin; Darragh G McArt; Richard D Kennedy; Paul B Mullan; Stephen McQuaid; Manuel Salto-Tellez; Niamh E Buckley
Journal: J Oncol Date: 2018-12-17 Impact factor: 4.375

2 in total